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Hyperplastic polyposis syndrome (HPS) is a rare condition 
characterized by the presence of numerous hyperplastic 
polyps (HPs) in the colon and rectum. Patients with HPS have 
an increased risk of colorectal cancer. This link is associated 
with gene mutations, especially B type Raf kinase (BRAF). 
However, a case of HPS associated with gene mutations has 
seldom been reported in Korea. Here, we describe a case 
of HPS in which a BRAF mutation was present in a 34-year-
old woman. She had more than 110 HPs in the stomach 
and colorectum, which we removed. All of the polyps were 
diagnosed histologically as HPs, and no adenomatous or 
malignant changes were noted. We performed a BRAF and 
K-ras mutation analysis as well as a microsatellite analysis on 
the resected colon polyps. BRAF mutations were found in the 
resected colon polyps, but there was no evidence of K-RAS 
mutation or microsatellite instability. (Gut Liver 2012;6:280-
283)
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers 
in the world. CRCs usually progress from adenomatous polyps, 
and the morphological and genetic progression of CRCs in an 
adenoma-adenocarcinoma sequence has been well described.
1,2 
A hyperplastic polyp (HP) is the most common histological type 
found among colorectal polyps, but they have been considered 
to have no malignant potential. However, recent studies have 
demonstrated that some HPs can develop into CRCs, especially 
in patients diagnosed with hyperplastic polyposis syndrome 
(HPS).
3,4 Recent studies have proposed that HPs arising in HPS 
progress toward adenocarcinoma through a “serrated neoplastic 
pathway” and that a B type Raf kinase (BRAF) proto-oncogene 
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mutation is one of the early genetic events in the initiation of 
this serrated pathway.
4-6 BRAF mutations have recently been 
found in 5% to 15% of CRCs.
7-9 We present a case of a 34-year-
old young woman with HPS who had a BRAF mutation.
CASE REPORT
A 34-year-old young woman visited our hospital for a gen-
eral health check. She had no family or personal history of 
colorectal carcinoma or other bowel diseases. However, she 
underwent a fine-needle aspiration biopsy (FNAB) for inciden-
tally discovered thyroid nodules 2 months previous. The FNAB 
of these nodules demonstrated bland-looking follicular cells. 
Her complete blood count showed no abnormal findings, and 
other laboratory tests and thyroid function tests were within the 
normal range. She underwent an esophagogastroduodenoscopy 
and colonoscopy. At the esophagogastroduodenoscopy, numer-
ous 0.2 to 0.7-cm-sized polyps were seen in the body and an-
trum of the stomach (Fig. 1). However, no lesions were observed 
in the bulb or secondary portion of the duodenum. During the 
colonoscopy, numerous 0.2 to 1.0-cm-sized polyps were also 
observed in the transverse colon, sigmoid colon and rectum. The 
polyps were mainly distributed on the sigmoid colon and rec-
tum. An upper gastrointestinal series showed no lesions in the 
small bowel. We removed 48 and 70 polyps from the stomach 
and colorectum, respectively. A histological examination of the 
resected polyps revealed HPs (Fig. 2). Based on our findings, the 
patient was diagnosed with coexisting HPS and gastric hyper-
plastic polyposis. We performed a BRAF and K-RAS mutation 
analysis as well as a microsatellite analysis on the representative 
HPs of the colon. BRAF mutations were found in the resected 
colon polyps (Fig. 3). The BRAF mutation identified was a mis-
sense mutation at codon 600, exon 15 replacing GTG (valine) 
with GAG (glutamic acid). A K-RAS mutation and microsatellite Ahn HS, et al: Hyperplastic Polyposis Syndrome Identified with a BRAF Mutation  281
instability (MSI), however, were not detected. The patient was 
discharged without complications and is on regular follow-up.
DISCUSSION
Sporadic HPs are of a benign nature and are usually small 
in size, multiply, increase with old age, and are mainly distrib-
uted in the sigmoid colon and rectum. However, CRCs arising 
in colorectal HPs or serrated adenomas (SAs), especially in pa-
tients diagnosed with HPS have been reported.
10-14 Additionally, 
recent studies proposed the HP-SA-carcinoma sequence as an 
alternative pathway for colorectal carcinogenesis.
4,15,16 HPS is an 
uncommon syndrome characterized by a diverse range of polyp 
types including multiple, large HPs and smaller numbers of SAs, 
traditional adenomas, and admixed hyperplastic/adenomatous 
polyps in the colon and rectum. In the World Health Organiza-
tion (WHO) HPS diagnostic criteria, Burt and Jass
17 defined HPS 
as at least five histologically diagnosed HPs occurring proximal 
to the sigmoid colon and of which more than two are greater 
than 1 cm in diameter, or more than 30 HPs in the whole colon 
and rectum, or any number of HPs proximal to the sigmoid 
colon in an individual who has a first-degree relative diagnosed 
with HPS. In such patients, polyps are usually sessile and 1-7 
mm in diameter, but larger and/or pedunculated HPs may also 
be observed. Some patients had adenomas or CRCs.
18-20 HPs 
of HPS progress to CRCs through the serrated pathway and a 
BRAF mutation is a key genetic event in the initiation of the 
serrated neoplastic pathway in the development of CRC.
4-6 The 
risk of malignant changes in HPs seems much higher when the 
HPs have histologically dysplastic features such as admixed 
polyps and SAs or when they are large, numerous, located 
on the right-sided colon, and present in younger patients.
21,22 
Genetic and epigenetic alterations in colorectal carcinoma are 
present in HPS. These alterations in  clude BRAF or K-RAS proto-
oncogene mutations and MSI .
14,23,24 BRAF makes a protein called 
B-RAF which is one of the members of the RAF family of ser-
ine/threonine kinases. B-RAF mediates cellular responses to 
growth signals through the RAS-RAF-MEK (mitogen-activated 
protein/extracellular signal-regulated kinase)-ERK (extracellular 
signal-regulated kinase)-MAP (mitogen-activated protein) ki-
nase pathway.
25,26 BRAF mutations have been found in various 
human cancers including CRCs and melanomas.
7,9,27-30 They have 
also been found in sporadic HPs and in SAs from patients with 
hyperplastic polyposis.
6,31,32 BRAF mutations are frequent in 
Fig. 1. (A) Esophagogastroduodeno-
scopic findings revealed numerous 
0.2- to 0.7-cm-sized polyps on the 
antrum of the stomach. (B) The colo-
noscopic findings revealed numer-
ous 0.2- to 0.6-cm-sized polyps on 
the rectum.
Fig. 2. Photomicrographs of a colon polyp. A hyperplastic polyp ex-
hibiting crypt serration and regular architecture with minimal crypt 
branching (H&E stain, ×100).
Fig. 3. B type Raf kinase (BRAF) mutation analysis. Direct DNA se-
quencing revealed a BRAF mutation at codon 600 and replacement 
in exon 15 of GAG (glutamic acid) with GTG (valine).282  Gut and Liver, Vol. 6, No. 2, April 2012
CRCs with a high level of MSI, but uncommon in microsatellite-
stable CRCs.
27-30 The frequency of BRAF mutations is much 
higher in HPS, especially younger patients and patients with 
large and right-sided polyps than in sporadic HPs which are 
predominantly present in the left-sided colon or rectum.
23 In 
contrast, K-RAS mutations are infrequent in HPS, but frequent 
in sporadic HPs.
14 Unlike BRAF, K-RAS mainly plays a key role 
in the development of CRC through the classical adenoma-
adenocarcinoma sequence, allowing the growth and progression 
of adenomatous colorectal polyps.
33 Some reports have demon-
strated that BRAF and K-RAS mutations are strongly inversely 
correlated.
7-9 It is rare that both BRAF and K-RAS mutations are 
present in different polyps from the same patient.
24 Therefore, 
molecular data such as BRAF or K-RAS can help in diagnosing 
HPS. In our case, the 34-year-old young woman had 48 and 70 
0.2 to 1.0-cm-sized HPs in the stomach and large bowel respec-
tively. We diagnosed HPS with gastric hyperplastic polyposis 
according to the WHO diagnostic criteria. We confirmed a BRAF 
mutation in the colon polyps. But, she had no K-RAS muta-
tion and MSI. A case of HPS identified with a BRAF mutation 
has been reported in only one case in Korea until now.
34 Fur-
thermore, HPS with multiple gastric HPs is very rare. We think 
that genetic alterations such as BRAF mutations in HPS may 
be frequently seen in patients who have hyperplastic polyposis 
in the stomach, colorectum or both. Although our case had no 
adenomatous or malignant changes, such patients may more 
frequently be accompanied with adenomatous or malignant 
changes in polyps. Because HPS with a BRAF mutation may 
carry a high risk for CRC, colonoscopic surveillance should be 
indicated. Endoscopic surveillance is recommended every 1 to 3 
years for patients with hyperplastic polyposis.
18 This endoscopic 
surveillance interval may be modified by other risk factors such 
as age, family or personal history of CRC, histology of polyps, 
and genetic mutations such as BRAF, and so on.
35
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
REFERENCES
1.   Fearon ER, Dang CV. Cancer genetics: tumor suppressor meets 
oncogene. Curr Biol 1999;9:R62-R65.
2. Chung DC. The genetic basis of colorectal cancer: insights into 
critical pathways of tumorigenesis. Gastroenterology 2000;119: 
854-865.
3.  Church JM, Fazio VW, Jones IT. Small colorectal polyps. Are they 
worth treating? Dis Colon Rectum 1988;31:50-53.
4.  Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in 
colorectal neoplasia. Gastroenterology 2002;123:862-876.
5. Hawkins NJ, Bariol C, Ward RL. The serrated neoplasia pathway. 
Pathology 2002;34:548-555.
6. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is as-
sociated with DNA methylation in serrated polyps and cancers of 
the colorectum. Gut 2004;53:1137-1144.
7.  Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in 
human cancer. Nature 2002;417:949-954.
8. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein 
B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mis-
match-repair status. Nature 2002;418:934.
9. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic 
patterns associated with BRAF and K-RAS mutations in colorectal 
neoplasia. Cancer Res 2002;62:6451-6455.
10.  Hawkins NJ, Ward RL. Sporadic colorectal cancers with micro-
satellite instability and their possible origin in hyperplastic polyps 
and serrated adenomas. J Natl Cancer Inst 2001;93:1307-1313.
11. Jass JR, Cottier DS, Pokos V, Parry S, Winship IM. Mixed epithe-
lial polyps in association with hereditary non-polyposis colorectal 
cancer providing an alternative pathway of cancer histogenesis. 
Pathology 1997;29:28-33.
12.  Iino H, Jass JR, Simms LA, et al. DNA microsatellite instability in 
hyperplastic polyps, serrated adenomas, and mixed polyps: a mild 
mutator pathway for colorectal cancer? J Clin Pathol 1999;52:5-9.
13.  Jass JR, Iino H, Ruszkiewicz A, et al. Neoplastic progression occurs 
through mutator pathways in hyperplastic polyposis of the col-
orectum. Gut 2000;47:43-49.
14. Rashid A, Houlihan PS, Booker S, Petersen GM, Giardiello FM, 
Hamilton SR. Phenotypic and molecular characteristics of hyper-
plastic polyposis. Gastroenterology 2000;119:323-332.
15.  Williams GT. Metaplastic (hyperplastic) polyps of the large bowel: 
benign neoplasms after all? Gut 1997;40:691-692.
16. Jass JR. Serrated route to colorectal cancer: back street or super 
highway? J Pathol 2001;193:283-285.
17.  Burt R, Jass JR. Hyperplastic polyposis. In: Hamilton SR, Aaltonen 
LA, eds. Pathology and genetics of tumours of the digestive sys-
tem. Lyon: IARC Press, 2000:135-136.
18.  Ferrandez A, Samowitz W, DiSario JA, Burt RW. Phenotypic 
characteristics and risk of cancer development in hyperplastic 
polyposis: case series and literature review. Am J Gastroenterol 
2004;99:2012-2018.
19. Lage P, Cravo M, Sousa R, et al. Management of Portuguese pa-
tients with hyperplastic polyposis and screening of at-risk first-
degree relatives: a contribution for future guidelines based on a 
clinical study. Am J Gastroenterol 2004;99:1779-1784.
20.  Hyman NH, Anderson P, Blasyk H. Hyperplastic polyposis and the 
risk of colorectal cancer. Dis Colon Rectum 2004;47:2101-2104.
21. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. 
Morphologic reappraisal of serrated colorectal polyps. Am J Surg 
Pathol 2003;27:65-81.
22. Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like co-
lon polyps that preceded microsatellite-unstable adenocarcinomas. 
Am J Clin Pathol 2003;119:778-796.
23.  Beach R, Chan AO, Wu TT, et al. BRAF mutations in aberrant Ahn HS, et al: Hyperplastic Polyposis Syndrome Identified with a BRAF Mutation  283
crypt foci and hyperplastic polyposis. Am J Pathol 2005;166:1069-
1075.
24. Carvajal-Carmona LG, Howarth KM, Lockett M, et al. Molecular 
classification and genetic pathways in hyperplastic polyposis syn-
drome. J Pathol 2007;212:378-385.
25.  Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new 
concepts of activation. Biol Cell 2001;93:53-62.
26.  Baccarini M. An old kinase on a new path: Raf and apoptosis. Cell 
Death Differ 2002;9:783-785.
27. Domingo E, Espín E, Armengol M, et al. Activated BRAF targets 
proximal colon tumors with mismatch repair deficiency and MLH1 
inactivation. Genes Chromosomes Cancer 2004;39:138-142.
28. Fransén K, Klintenäs M, Osterström A, Dimberg J, Monstein HJ, 
Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-
1 genes in human colorectal adenocarcinomas. Carcinogenesis 
2004;25:527-533.
29. Oliveira C, Pinto M, Duval A, et al. BRAF mutations characterize 
colon but not gastric cancer with mismatch repair deficiency. On-
cogene 2003;22:9192-9196.
30. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in 
colon cancer are not likely attributable to defective DNA mismatch 
repair. Cancer Res 2003;63:5209-5212.
31. Chan TL, Zhao W, Leung SY, Yuen ST; Cancer Genome Project. 
BRAF and K-RAS mutations in colorectal hyperplastic polyps and 
serrated adenomas. Cancer Res 2003;63:4878-4881.
32.  Yang S, Farraye FA, Mack C, Posnik O, O’Brien MJ. BRAF and K-
RAS mutations in hyperplastic polyps and serrated adenomas of 
the colorectum: relationship to histology and CpG island methyla-
tion status. Am J Surg Pathol 2004;28:1452-1459.
33. Risio M, Malacarne D, Giaretti W. K-RAS transitions and villous 
growth in colorectal adenomas. Cell Oncol 2005;27:363-366.
34. Seong MK, Shim JS, Hwang TS, Kim JH. Hyperplastic polyposis 
associated with two synchronous colon cancers. J Korean Soc Co-
loproctol 2009;25:202-206.
35. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyper-
plastic polyps and serrated adenomas of the colon: classification, 
molecular genetics, natural history, and clinical management. 
Gastroenterol Clin North Am 2008;37:25-46.